Opinion|Videos|October 25, 2024
Therapies Beyond the Front Line for SCLC
Key Takeaways
- Tarlatamab is a newly approved therapy, marking progress beyond first-line treatments for SCLC.
- Researchers are exploring novel agents and combination therapies to enhance patient outcomes in SCLC.
Panelists discuss how treatment options for small cell lung cancer (SCLC) extend beyond first-line therapies and the recently approved tarlatamab, exploring existing treatments in the second-line and beyond while also highlighting promising ongoing clinical trials and emerging therapies that show potential for improving outcomes in SCLC patients.
Advertisement
Episodes in this series
We’ve discussed first-line therapies and a newly approved therapy tarlatamab.
- Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
- What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?
How do you see the management of SCLC evolving in the future?
Advertisement
Related to this article
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5